CG Oncology Inc. (CGON) Stock: Price, Forecast & Analyst Target
CG Oncology Inc. (CGON) — MoonshotScore 25/100 (Weak band), calculated Oct 4, 2026. Price $67.38 (-1.42%), as of the Oct 2, 2026 trading session; market cap $5.94B. Expected results Nov 13, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 5.78× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Nov 13, 2026
CG Oncology Inc. · CGON · NASDAQ · Healthcare · Biotechnology
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · CG Oncology (CGON)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but bottom-tier quality and stalling growth; the market is already moving on it. Business Quality: Poor; Financial Safety: Fortress; Valuation: Full; Growth Durability: Fading; Momentum: Rising.
- quarterly revenue $1M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 2 of 8
- Altman Z 62.83 · Piotroski F 3
Holding back: weak fundamentals, soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 25 | Weak | |
| 25 | Weak | |
| 30 | Weak | |
| 30 | Weak | |
| 25 | Weak | |
| 25 | Weak |
The score was 25 in the stored Oct 3, 2026 snapshot and remains 25 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Momentum +2 and Growth Durability +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $67.38 |
| Change on the day | -1.42% |
| 52-week range | $35.80–$80.97 |
| Market capitalisation | $5.94B |
| Price / earnings (trailing) | -22.33 |
| Shares traded on the day | 1.54M |
| Beta (volatility vs the S&P 500) | 0.24 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for CG Oncology (CGON): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the CGON film — every key number, told as a short cinematic story
~2 min · open the film
What is CG Oncology (CGON), and what does it report?
Short answer · as of
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. CG Oncology Inc. (CGON) is listed on NASDAQ. CG Oncology Inc. (CGON) is classified as Healthcare / Biotechnology. SEC filing business address: 3000 Pegasus Park Drive, Suite 1640, Dallas, TX, 75247. It employs 142 people and is led by Arthur Kuan. In Q2 FY2026 it reported revenue of $1M and net income of -$79M. The market values it at $5.94B.
What do the latest results show for CG Oncology (CGON)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1M. Against analyst estimates the company has EPS beat 2 of 8 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $1.16M Jun 30, 2026
- Latest quarter · R&D
- $54.66M Jun 30, 2026
- Latest quarter · SG&A
- $28.98M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$86.40M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $1.16M | $54.66M | $28.98M | −$86.40M |
| Mar 31, 2026 | $1.08M | $43.73M | $20.78M | −$66.39M |
| Dec 31, 2025 | $2.32M | $29.96M | $17.99M | −$48.70M |
| Sep 30, 2025 | $1.67M | $27.88M | $23.33M | −$51.13M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.16M Aug 6, 2026
- Latest report · revenue estimate
- $360,805 Aug 6, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 6, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 6, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 6, 2026 | $1.16M | $360,805 | −$0.9000 | −$0.6642 |
| May 8, 2026 | $1.08M | $453,034 | −$0.7100 | −$0.5800 |
| Feb 27, 2026 | $2.31M | $450,538 | −$0.5100 | −$0.6100 |
| Nov 14, 2025 | $1.67M | $59,364 | −$0.5700 | −$0.5590 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1M | -$79M | -$0.90 (diluted) |
| Q1 FY2026 | $1M | -$60M | -$0.71 (diluted) |
| Q4 FY2025 | $2M | -$41M | -$0.52 (diluted) |
| Q3 FY2025 | $2M | -$44M | -$0.57 (diluted) |
What are the financial strengths and risks for CG Oncology (CGON)?
Short answer
Cash and short-term investments were $1.03B at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$46.41M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway. The MoonshotScore pillars rate balance-sheet strength, positive momentum as strengths. What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z 62.83 · Piotroski F 3. Trailing ratios: ROE -23.3% · ROA -16.4% · current ratio 31.30 · earnings yield -3.1% · free-cash-flow yield -2.6%.
Data-derived red flags
- Negative return on equity (-23.3%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$46.41M Jun 30, 2026
- Previous quarter · operating cash flow
- −$56.94M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$46.41M | −$470,000 |
| Mar 31, 2026 | −$56.94M | −$300,000 |
| Dec 31, 2025 | −$36.22M | −$10,000 |
| Sep 30, 2025 | −$38.89M | −$100,000 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at CG Oncology (CGON)?
Short answer · as of
The next earnings report is expected on Nov 13, 2026. Current published price targets run low $80.00 · high $100.00 · consensus $86.50 · median $83.00 against a quoted price of $67.38 (as of Oct 2, 2026).
How does CG Oncology compare with its peers?
Short answer
CG Oncology's score ranks 4th of 4 in the bounded comparison shown, against 3 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $38.02 Oct 2, 2026 | $3.68B | 56 5-pillar Oct 4, 2026 | |
| $72.10 Oct 2, 2026 | $3.52B | 50 5-pillar Oct 4, 2026 | |
| $18.57 Oct 2, 2026 | $3.43B | 35 5-pillar Oct 4, 2026 | |
| CG Oncology (CGON) — this page | $67.38 | $5.94B | 25 |
| $40.50 Sep 14, 2026 | $6.27B | — Model unavailable | |
| $135.07 Sep 15, 2026 | $8.36B | — Model unavailable | |
| $302.96 Date unavailable | $6.07B | — Model unavailable | |
| $159.56 Date unavailable | $6.40B | — Model unavailable | |
| $14.74 Date unavailable | $5.12B | — Model unavailable | |
| $84.52 Date unavailable | $5.10B | — Model unavailable | |
| $41.75 Date unavailable | $7.00B | — Model unavailable | |
| $116.76 Date unavailable | $4.88B | — Model unavailable | |
| $41.40 Date unavailable | $4.45B | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $80.00 – $100.00
- Consensus target
- $86.50
- Median target
- $83.00
Consensus record · Captured .
Measured against a quoted price of $67.38 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 15, 2026
- Transactions
- 41
- Identified insiders
- 11
- Purchases
- 1
- Sales
- 9
- Other transactions
- 31
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 246 Period end Jun 30, 2026
- Previous quarter · holders
- 246 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Rtw Investments, LP | 8,514,590 |
| T. Rowe Price Investment Management, INC. | 6,616,899 |
| Decheng Capital LLC | 6,371,669 |
| Blackrock, INC. | 6,256,288 |
| Wellington Management Group Llp | 5,324,751 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about CG Oncology (CGON)?
What Investors Ask About CG Oncology (CGON) — Healthcare
These answers are editorial: 1 of these 9 answers is drawn from the CGON research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for CGON?
CGON carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. CG Oncology Inc. is a clinical-stage biopharmaceutical company focused on developing bladder-sparing therapeutics for bladder cancer patients.
Is CGON a good stock to buy?
Stock Expert AI does not rate CGON buy, sell or hold. CG Oncology Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CGON stock price today?
The last price recorded on this page for CG Oncology Inc. (CGON) is $67.38, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CGON price target?
The analyst consensus price target for CG Oncology Inc. (CGON) is $86.50 (range $80.00 to $100.00, median $83.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for CGON?
The main risks for CGON include the inherent uncertainties associated with clinical-stage drug development, such as the potential for clinical trial failures or delays. Competition from existing and emerging therapies in the bladder cancer treatment landscape could impact CGON's market share.
What are the key factors to evaluate for CGON?
CG Oncology Inc. (CGON) holds a MoonshotScore in the low range. Analysts target $86.50 (+28%). This could lead to increased market penetration and revenue growth. Not financial advice.
How frequently does CGON data refresh on this page?
CGON's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CGON's recent stock price performance?
CG Oncology Inc. (CGON) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel therapeutic approach with cretostimogene. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CGON overvalued or undervalued right now?
CG Oncology Inc. (CGON) is loss-making, so its trailing P/E is negative (-22.33x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Analysts target $86.50 (+28%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (85 figures)
The 85 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 3000 Pegasus Park Drive, Suite 1640, Dallas, TX, 75247 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "3000 Pegasus Park Drive, Dallas, TX, 75247, US". The FMP company description names Irvine, California as the headquarters; this page uses the address in this row. |
FMP — 76 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 13, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $67.38 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T21:24:39.042Z. | |
px.change | Change on the day | -1.42% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $5.94B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T21:24:37.970Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$0.97 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $1M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $35.80–$80.97 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | -22.33 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.54M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.24 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Biotechnology | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 2836 — Biological Products, (No Diagnostic Substances). | |
id.employees | Employees | 142 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
id.ceo | Chief executive | Arthur Kuan | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_income | Net income, Q2 FY2026 | -$79M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $10.36M, net result −$12.84M; FY2022 revenue $190,000, net result −$35.44M; FY2023 revenue $200,000, net result −$48.61M; FY2024 revenue $1.14M, net result −$88.04M; FY2025 revenue $4.04M, net result −$160.99M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | License And Collaboration Revenue $806,000 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | -82.7% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $1.16M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $54.66M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $28.98M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$86.40M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $1.08M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $43.73M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $20.78M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$66.39M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $2.32M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $29.96M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $17.99M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$48.70M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $1.67M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $27.88M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $23.33M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$51.13M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-06.revenue_actual | Revenue · reported — report date 2026-08-06 | $1.16M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.revenue_estimated | Revenue · estimate — report date 2026-08-06 | $360,805 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_actual | EPS · reported — report date 2026-08-06 | −$0.9000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_estimated | EPS · estimate — report date 2026-08-06 | −$0.6642 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-08.revenue_actual | Revenue · reported — report date 2026-05-08 | $1.08M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-08.revenue_estimated | Revenue · estimate — report date 2026-05-08 | $453,034 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-08.eps_actual | EPS · reported — report date 2026-05-08 | −$0.7100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-08.eps_estimated | EPS · estimate — report date 2026-05-08 | −$0.5800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-27.revenue_actual | Revenue · reported — report date 2026-02-27 | $2.31M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-27.revenue_estimated | Revenue · estimate — report date 2026-02-27 | $450,538 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-27.eps_actual | EPS · reported — report date 2026-02-27 | −$0.5100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-27.eps_estimated | EPS · estimate — report date 2026-02-27 | −$0.6100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-14.revenue_actual | Revenue · reported — report date 2025-11-14 | $1.67M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-14.revenue_estimated | Revenue · estimate — report date 2025-11-14 | $59,364 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-14.eps_actual | EPS · reported — report date 2025-11-14 | −$0.5700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-14.eps_estimated | EPS · estimate — report date 2025-11-14 | −$0.5590 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $1.03B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$46.41M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $8.82M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 5.77× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$46.41M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$56.94M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$470,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$300,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$36.22M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$10,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$38.89M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$100,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt | Stored analyst price targets | low $80.00 · high $100.00 · consensus $86.50 · median $83.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $80.00 – $100.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $86.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $83.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 41 transactions · 1 purchases, 9 sales, 31 other transactions · 11 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 15, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 246 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 246 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Rtw Investments, LP — shares in provider snapshot | 8,514,590 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | T. Rowe Price Investment Management, INC. — shares in provider snapshot | 6,616,899 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Decheng Capital LLC — shares in provider snapshot | 6,371,669 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Blackrock, INC. — shares in provider snapshot | 6,256,288 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Wellington Management Group Llp — shares in provider snapshot | 5,324,751 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 2 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 62.83 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -23.3% · ROA -16.4% · current ratio 31.30 · earnings yield -3.1% · free-cash-flow yield -2.6% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 5.78× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $1.03B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-06.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($1.16M) with the recorded estimate ($360,805) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-06.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.9000) with the recorded estimate (−$0.6642) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 25 of 100 · Weak · pillars 19 / 98 / 43 / 24 / 79 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 25 (stored snapshot Oct 3, 2026) → 25 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-06. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-06.revenue_actual,earn.history.depth.2026-08-06.revenue_estimated,earn.history.depth.2026-08-06.revenue_actual.comparison,earn.history.depth.2026-08-06.eps_actual.comparison,earn.history.depth.2026-08-06.eps_actual,earn.history.depth.2026-08-06.eps_estimated,earn.history.depth.2026-05-08.revenue_actual,earn.history.depth.2026-05-08.revenue_estimated,earn.history.depth.2026-05-08.eps_actual,earn.history.depth.2026-05-08.eps_estimated,earn.history.depth.2026-02-27.revenue_actual,earn.history.depth.2026-02-27.revenue_estimated,earn.history.depth.2026-02-27.eps_actual,earn.history.depth.2026-02-27.eps_estimated,earn.history.depth.2025-11-14.revenue_actual,earn.history.depth.2025-11-14.revenue_estimated,earn.history.depth.2025-11-14.eps_actual,earn.history.depth.2025-11-14.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.